Advaxis (NASDAQ: ADXS) is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
Type
Public
HQ
Princeton, US
Founded
2002
Size (employees)
108 (est)+20%
Advaxis was founded in 2002 and is headquartered in Princeton, US
Report incorrect company information

Key People/Management at Advaxis

Anthony Lombardo

Anthony Lombardo

Interim CEO
Thomas J. McKearn

Thomas J. McKearn

Director
Roni A. Appel

Roni A. Appel

Director
Richard Berman

Richard Berman

Director
Robert G. Petit

Robert G. Petit

Executive Vice President and Chief Scientific Officer

Advaxis Office Locations

Advaxis has an office in Princeton
Princeton, US (HQ)
305 College Rd E
Show all (1)
Report incorrect company information

Advaxis Financials and Metrics

Advaxis Financials

Advaxis's revenue was reported to be $12.03 m in FY, 2017
USD

Revenue (Q1, 2018)

2.1 m

Net income (Q1, 2018)

(20.5 m)

EBIT (Q1, 2018)

(20.5 m)

Market capitalization (20-Apr-2018)

68.6 m

Cash (31-Jan-2018)

25.9 m
Advaxis's current market capitalization is $68.6 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

1.9 m1 m4 m12 m

Revenue growth, %

(46%)

General and administrative expense

31.7 m38.7 m

R&D expense

48.8 m71.9 m
Quarterly
USDQ1, 2014Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

250 k3.8 m3.4 m3.1 m2.1 m

General and administrative expense

4.4 m6.3 m7.1 m6.8 m6.4 m7.3 m7.8 m18.1 m5.5 m

R&D expense

1.6 m7.3 m13.1 m8.8 m10.1 m13.6 m16.3 m17.8 m17.1 m

Operating expense total

6 m13.6 m20.2 m15.6 m16.6 m21 m24.1 m35.9 m22.6 m
Annual
USDFY, 2013FY, 2014FY, 2016FY, 2017

Cash

20.6 m17.6 m112.8 m23.9 m

Accounts Receivable

80.1 k

Inventories

Current Assets

20.8 m20.5 m159.9 m81.2 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q1, 2018

Cash

16 m27.6 m22.1 m30.6 m45.9 m25.9 m

Current Assets

16.2 m28 m23.3 m31.5 m48.6 m64 m

PP&E

7.9 m

Total Assets

18.9 m30.9 m26.1 m34.5 m51.7 m77.4 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(20 m)(16.5 m)(73.6 m)(93.4 m)

Depreciation and Amortization

19.3 k27.6 k283.5 k790.6 k

Inventories

Accounts Payable

(1.9 m)8.4 m1.2 m
Quarterly
USDQ1, 2014Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(5.2 m)(13.6 m)(19.8 m)(15.5 m)(16.5 m)(17.1 m)(20.5 m)

Depreciation and Amortization

6.9 k

Accounts Payable

2.2 m843.5 k5.6 m2.6 m3.5 m9.7 m3 m

Cash From Operating Activities

(5 m)
USDY, 2018

Financial Leverage

2 x
Show all financial metrics
Report incorrect company information

Advaxis News and Updates

Globalized Anal Cancer Market Pipeline Overview 2018 | Key Manufacturers, Market Growth Analysis and Forecast to 2027; Marketresearchfuture.com

The report titled “Anal Cancer Market -Forecast to 2027″ is a direct appreciation by Market Research Future of the market potential of the Anal Cancer Market. The report intends to provide accurate and meaningful insights, both quantitative as well as qualitative. It can be said with high confidence…

Worldwide Anal Cancer Flourishes Relentlessly; Asserts MRFR Unleashing Industry Forecast Up To 2027

Market Research Future published a half cooked research report on “Global Anal Cancer Market - Forecast to 2027”-Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2027 Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information